The Latest Cardiac and Vascular News
Company Plans to Meet with FDA in Q1 to Discuss Results of GALACTIC-HF Enrollment Completed in Cohort 2 of REDWOOD-HCM; Results Expected Mid-Year Company Provides 2021 Financial Guidance; More Than Two Years of Cash Runway SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) reported […]
Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing Conference call begins today at 4:30 p.m. (ET) BASKING RIDGE, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies […]
SUNNYVALE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced positive results from a comparative-effectiveness study have been published in JAMA Network Open. The study found the availability of TCAR at a hospital […]
Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases Silence to receive $2 million research milestone payment Silence is also eligible to receive up to $2 billion in total milestone payments across all three targets and tiered double-digit royalties on […]
– Updates from ongoing PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH) presented at the American Heart Association (AHA) 2020 Scientific Sessions – – STELLAR Phase 3 trial initiated with sotatercept in PAH – – Acceleron recognized approximately $23.0 million in royalty […]
Enrollment with advanced generation device for complete cerebral protection nearing halfway mark in clinical study in Germany and Poland AACHEN, Germany–(BUSINESS WIRE)–Protembis GmbH, a privately held emerging medical device company, announced today the successful completion of 20 clinical cases in its European regulatory study of the ProtEmbo® Cerebral Protection System. The […]
Fourth quarter 2020 revenues of $711.2 million, up 4.4% versus prior year period on an as-reported basis; up 2.3% on a constant currency basis Fourth quarter 2020 GAAP diluted EPS from continuing operations of $1.62, compared to $2.28 in the prior year period Fourth quarter 2020 adjusted diluted EPS from continuing […]
Q4 2020 reported revenue of $258.0 million, approximately equal to Q4 2019 revenue Q4 2020 core revenue on a constant currency basis* down (1.0)% compared to Q4 2019 Q4 2020 GAAP EPS of $0.27, compared to GAAP loss per share of ($0.08) in Q4 2019 Q4 2020 non-GAAP EPS* of […]
ST. LOUIS, Feb. 25, 2021 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2020. “2020 was a year of significant progress despite a challenging macro environment,” said […]
VANCOUVER and MINNEAPOLIS, Feb. 24, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), has received written notification (the “Nasdaq Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum market value requirement set forth in the rules for […]
